APO RESEARCH · REPORT
Pulmonary Drug Delivery Systems
Pulmonary drug delivery systems are used to the treatment of various respiratory diseases like asthma and chronic obstructive pulmonary disease (COPD), delivering locally acting drugs directly to their site of action. Advantages of pulmonary drug delivery systems over oral drugs is the excellent capability of absorbing pharmaceuticals, due to the large absorptive surface area of lungs (approximately 70-140 m2 in adult humans having extremely thin absorptive mucosal membrane) and good blood supply.
Product & engineering
Understand the product.
Pulmonary drug delivery systems are used to the treatment of various respiratory diseases like asthma and chronic obstructive pulmonary disease (COPD), delivering locally acting drugs directly to their site of action. Advantages of pulmonary drug delivery systems over oral drugs is the excellent capability of absorbing pharmaceuticals, due to the large absorptive surface area of lungs (approximately 70-140 m2 in adult humans having extremely thin absorptive mucosal membrane) and good blood supply.
Selected research
Industry Research
Pulmonary Drug Delivery Systems Industry Research Report 2026
Market perspective
Pulmonary drug delivery systems are used to the treatment of various respiratory diseases like asthma and chronic obstructive pulmonary disease (COPD), delivering locally acting drugs directly to their site of action. Advantages of pulmonary drug delivery systems over oral drugs is the excellent capability of absorbing pharmaceuticals, due to the large absorptive surface area of lungs (approximately 70-140 m2 in adult humans having extremely thin absorptive mucosal membrane) and good blood supply.
The major players in global Pulmonary Drug Delivery Systems market include 3M, GSK, AstraZeneca, etc. The top 3 players occupy about 60% shares of the global market. Europe and North America are main markets, they occupy over 75% of the global market. Metered Dose Inhaler (MDI) is the main type, with a share over 60%. COPD is the main application, which holds a share over 50%.
Report Scope
Read the full market overview
This report quantifies the global Pulmonary Drug Delivery Systems market in terms of revenue (US$ million) and, where applicable, sales volume (M Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/M Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Pulmonary Drug Delivery Systems Market by Company
3M
GSK
AstraZeneca
Cipla
Chiesi
Boehringer Ingelheim
Aptar
Novartis
Philips Respironics
Omron Healthcare
PARI
Skyepharma
CareFusion
Shanghai Huarui
Taian Character
Chia Tai Tianqing
Pulmonary Drug Delivery Systems Segment by Type
Nebulizers
Dry Powder Inhaler (DPI)
Metered Dose Inhaler (MDI)
Pulmonary Drug Delivery Systems Segment by Application
COPD
Asthma
Others
Pulmonary Drug Delivery Systems Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pulmonary Drug Delivery Systems market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Pulmonary Drug Delivery Systems and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pulmonary Drug Delivery Systems.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Pulmonary Drug Delivery Systems manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Pulmonary Drug Delivery Systems by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Pulmonary Drug Delivery Systems in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Nebulizers
- Dry Powder Inhaler (DPI)
- Metered Dose Inhaler (MDI)
Applications
- COPD
- Asthma
- Others
Companies covered
- 3M
- GSK
- AstraZeneca
- Cipla
- Chiesi
- Boehringer Ingelheim
- Aptar
- Novartis
- Philips Respironics
- Omron Healthcare
- PARI
- Skyepharma
- CareFusion
- Shanghai Huarui
- Taian Character
- Chia Tai Tianqing
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Pulmonary Drug Delivery Systems Market Size (2021-2032)
- 2.2.2 Global Pulmonary Drug Delivery Systems Sales (2021-2032)
- 2.2.3 Global Pulmonary Drug Delivery Systems Market Average Price (2021-2032)
- 2.3 Pulmonary Drug Delivery Systems by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Nebulizers
- 2.3.3 Dry Powder Inhaler (DPI)
- 2.3.4 Metered Dose Inhaler (MDI)
- 2.4 Pulmonary Drug Delivery Systems by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 COPD
- 2.4.3 Asthma
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Pulmonary Drug Delivery Systems Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Pulmonary Drug Delivery Systems Sales (M Units) of Manufacturers (2021-2026)
- 3.3 Global Pulmonary Drug Delivery Systems Revenue of Manufacturers (2021-2026)
- 3.4 Global Pulmonary Drug Delivery Systems Average Price by Manufacturers (2021-2026)
- 3.5 Global Pulmonary Drug Delivery Systems Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Pulmonary Drug Delivery Systems, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Pulmonary Drug Delivery Systems, Product Type & Application
- 3.8 Global Manufacturers of Pulmonary Drug Delivery Systems, Established Date
- 3.9 Global Pulmonary Drug Delivery Systems Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 3M
- 4.1.1 3M Company Information
- 4.1.2 3M Business Overview
- 4.1.3 3M Pulmonary Drug Delivery Systems Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 3M Pulmonary Drug Delivery Systems Product Portfolio
- 4.1.5 3M Recent Developments
- 4.2 GSK
- 4.2.1 GSK Company Information
- 4.2.2 GSK Business Overview
- 4.2.3 GSK Pulmonary Drug Delivery Systems Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 GSK Pulmonary Drug Delivery Systems Product Portfolio
- 4.2.5 GSK Recent Developments
- 4.3 AstraZeneca
- 4.3.1 AstraZeneca Company Information
- 4.3.2 AstraZeneca Business Overview
- 4.3.3 AstraZeneca Pulmonary Drug Delivery Systems Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 AstraZeneca Pulmonary Drug Delivery Systems Product Portfolio
- 4.3.5 AstraZeneca Recent Developments
- 4.4 Cipla
- 4.4.1 Cipla Company Information
- 4.4.2 Cipla Business Overview
- 4.4.3 Cipla Pulmonary Drug Delivery Systems Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Cipla Pulmonary Drug Delivery Systems Product Portfolio
- 4.4.5 Cipla Recent Developments
- 4.5 Chiesi
- 4.5.1 Chiesi Company Information
- 4.5.2 Chiesi Business Overview
- 4.5.3 Chiesi Pulmonary Drug Delivery Systems Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Chiesi Pulmonary Drug Delivery Systems Product Portfolio
- 4.5.5 Chiesi Recent Developments
- 4.6 Boehringer Ingelheim
- 4.6.1 Boehringer Ingelheim Company Information
- 4.6.2 Boehringer Ingelheim Business Overview
- 4.6.3 Boehringer Ingelheim Pulmonary Drug Delivery Systems Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Boehringer Ingelheim Pulmonary Drug Delivery Systems Product Portfolio
- 4.6.5 Boehringer Ingelheim Recent Developments
- 4.7 Aptar
- 4.7.1 Aptar Company Information
- 4.7.2 Aptar Business Overview
- 4.7.3 Aptar Pulmonary Drug Delivery Systems Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Aptar Pulmonary Drug Delivery Systems Product Portfolio
- 4.7.5 Aptar Recent Developments
- 4.8 Novartis
- 4.8.1 Novartis Company Information
- 4.8.2 Novartis Business Overview
- 4.8.3 Novartis Pulmonary Drug Delivery Systems Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Novartis Pulmonary Drug Delivery Systems Product Portfolio
- 4.8.5 Novartis Recent Developments
- 4.9 Philips Respironics
- 4.9.1 Philips Respironics Company Information
- 4.9.2 Philips Respironics Business Overview
- 4.9.3 Philips Respironics Pulmonary Drug Delivery Systems Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Philips Respironics Pulmonary Drug Delivery Systems Product Portfolio
- 4.9.5 Philips Respironics Recent Developments
- 4.10 Omron Healthcare
- 4.10.1 Omron Healthcare Company Information
- 4.10.2 Omron Healthcare Business Overview
- 4.10.3 Omron Healthcare Pulmonary Drug Delivery Systems Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Omron Healthcare Pulmonary Drug Delivery Systems Product Portfolio
- 4.10.5 Omron Healthcare Recent Developments
- 4.11 PARI
- 4.11.1 PARI Company Information
- 4.11.2 PARI Business Overview
- 4.11.3 PARI Pulmonary Drug Delivery Systems Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 PARI Pulmonary Drug Delivery Systems Product Portfolio
- 4.11.5 PARI Recent Developments
- 4.12 Skyepharma
- 4.12.1 Skyepharma Company Information
- 4.12.2 Skyepharma Business Overview
- 4.12.3 Skyepharma Pulmonary Drug Delivery Systems Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Skyepharma Pulmonary Drug Delivery Systems Product Portfolio
- 4.12.5 Skyepharma Recent Developments
- 4.13 CareFusion
- 4.13.1 CareFusion Company Information
- 4.13.2 CareFusion Business Overview
- 4.13.3 CareFusion Pulmonary Drug Delivery Systems Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 CareFusion Pulmonary Drug Delivery Systems Product Portfolio
- 4.13.5 CareFusion Recent Developments
- 4.14 Shanghai Huarui
- 4.14.1 Shanghai Huarui Company Information
- 4.14.2 Shanghai Huarui Business Overview
- 4.14.3 Shanghai Huarui Pulmonary Drug Delivery Systems Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Shanghai Huarui Pulmonary Drug Delivery Systems Product Portfolio
- 4.14.5 Shanghai Huarui Recent Developments
- 4.15 Taian Character
- 4.15.1 Taian Character Company Information
- 4.15.2 Taian Character Business Overview
- 4.15.3 Taian Character Pulmonary Drug Delivery Systems Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 Taian Character Pulmonary Drug Delivery Systems Product Portfolio
- 4.15.5 Taian Character Recent Developments
- 4.16 Chia Tai Tianqing
- 4.16.1 Chia Tai Tianqing Company Information
- 4.16.2 Chia Tai Tianqing Business Overview
- 4.16.3 Chia Tai Tianqing Pulmonary Drug Delivery Systems Sales, Revenue and Gross Margin (2021-2026)
- 4.16.4 Chia Tai Tianqing Pulmonary Drug Delivery Systems Product Portfolio
- 4.16.5 Chia Tai Tianqing Recent Developments
5 Global Pulmonary Drug Delivery Systems Market Scenario by Region
- 5.1 Global Pulmonary Drug Delivery Systems Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Pulmonary Drug Delivery Systems Sales by Region: 2021-2032
- 5.2.1 Global Pulmonary Drug Delivery Systems Sales by Region: 2021-2026
- 5.2.2 Global Pulmonary Drug Delivery Systems Sales by Region: 2027-2032
- 5.3 Global Pulmonary Drug Delivery Systems Revenue by Region: 2021-2032
- 5.3.1 Global Pulmonary Drug Delivery Systems Revenue by Region: 2021-2026
- 5.3.2 Global Pulmonary Drug Delivery Systems Revenue by Region: 2027-2032
- 5.4 North America Pulmonary Drug Delivery Systems Market Facts & Figures by Country
- 5.4.1 North America Pulmonary Drug Delivery Systems Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Pulmonary Drug Delivery Systems Sales by Country (2021-2032)
- 5.4.3 North America Pulmonary Drug Delivery Systems Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Pulmonary Drug Delivery Systems Market Facts & Figures by Country
- 5.5.1 Europe Pulmonary Drug Delivery Systems Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Pulmonary Drug Delivery Systems Sales by Country (2021-2032)
- 5.5.3 Europe Pulmonary Drug Delivery Systems Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Pulmonary Drug Delivery Systems Market Facts & Figures by Country
- 5.6.1 Asia Pacific Pulmonary Drug Delivery Systems Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Pulmonary Drug Delivery Systems Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Pulmonary Drug Delivery Systems Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Pulmonary Drug Delivery Systems Market Facts & Figures by Country
- 5.7.1 South America Pulmonary Drug Delivery Systems Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Pulmonary Drug Delivery Systems Sales by Country (2021-2032)
- 5.7.3 South America Pulmonary Drug Delivery Systems Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Pulmonary Drug Delivery Systems Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Pulmonary Drug Delivery Systems Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Pulmonary Drug Delivery Systems Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Pulmonary Drug Delivery Systems Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Pulmonary Drug Delivery Systems Sales by Type (2021-2032)
- 6.1.1 Global Pulmonary Drug Delivery Systems Sales by Type (2021-2032) & (M Units)
- 6.1.2 Global Pulmonary Drug Delivery Systems Sales Market Share by Type (2021-2032)
- 6.2 Global Pulmonary Drug Delivery Systems Revenue by Type (2021-2032)
- 6.2.1 Global Pulmonary Drug Delivery Systems Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Pulmonary Drug Delivery Systems Revenue Market Share by Type (2021-2032)
- 6.3 Global Pulmonary Drug Delivery Systems Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Pulmonary Drug Delivery Systems Sales by Application (2021-2032)
- 7.1.1 Global Pulmonary Drug Delivery Systems Sales by Application (2021-2032) & (M Units)
- 7.1.2 Global Pulmonary Drug Delivery Systems Sales Market Share by Application (2021-2032)
- 7.2 Global Pulmonary Drug Delivery Systems Revenue by Application (2021-2032)
- 7.2.1 Global Pulmonary Drug Delivery Systems Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Pulmonary Drug Delivery Systems Revenue Market Share by Application (2021-2032)
- 7.3 Global Pulmonary Drug Delivery Systems Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Pulmonary Drug Delivery Systems Value Chain Analysis
- 8.1.1 Pulmonary Drug Delivery Systems Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Pulmonary Drug Delivery Systems Production Mode & Process
- 8.2 Pulmonary Drug Delivery Systems Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Pulmonary Drug Delivery Systems Distributors
- 8.2.3 Pulmonary Drug Delivery Systems Customers
9 Global Pulmonary Drug Delivery Systems Analyzing Market Dynamics
- 9.1 Pulmonary Drug Delivery Systems Industry Trends
- 9.2 Pulmonary Drug Delivery Systems Industry Drivers
- 9.3 Pulmonary Drug Delivery Systems Industry Opportunities and Challenges
- 9.4 Pulmonary Drug Delivery Systems Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst